Generated by AI
Lyell Immunopharma, Inc. is a clinical-stage cell therapy company focused on developing next-generation CAR T-cell therapies for cancer. The company is advancing a pipeline of product candidates designed to improve T-cell performance by helping cells resist exhaustion, persist longer, and maintain stronger tumor-fighting activity in challenging cancer environments. Its current programs target both hematologic malignancies and solid tumors, with work spanning blood cancers such as large B-cell lymphoma and solid-tumor indications including colorectal cancer. Lyell Immunopharma combines genetic and epigenetic T-cell reprogramming technologies with manufacturing capabilities to support product development and clinical testing. Based in South San Francisco, California, the company plays a role in the broader immunotherapy market by focusing on engineered cell-based treatments intended to address major unmet needs in oncology.
Website201 Haskins Way
South San Francisco, CA, 94080
United States
The latest articles about LYEL.
Summary of Mar 9's posts. Generated by AI.
No summary yet.
Summary of Jul 29's posts. Generated by AI.
No summary yet.
Summary of Nov 13's posts. Generated by AI.
Investors talking about LYEL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.